Prot #0610-02: A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients wi

Project: Research project

Project Details

StatusActive
Effective start/end date10/2/18 → 10/2/24

Funding

  • Parexel (Prot #0610-02)
  • Constellation Pharmaceuticals, Inc. (Prot #0610-02)